SCHEMBL26969724

SCHEMBL26969724

CN1Cc2cc(S(=O)(=O)N3CC4(CCCC4)c4ccccc43)ccc2C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.38
BRD4 O60885 1/20 0.37
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
NOTUM Q6P988 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TP53 P04637 1/20 0.35
PKM P14618 2/20 0.35
ATM Q13315 1/20 0.35
NPY5R Q15761 6/20 0.34
PRF1 P14222 2/20 0.34
KCNN4 O15554 1/20 0.34
KCNA3 P22001 1/20 0.34
OPRM1 P35372 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
HTR1A P08908 1/20 0.33
DRD4 P21917 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR7 P34969 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26969760 0.82 ACLY (0.38) ACLYALDH1A1TSHRNOTUMHSD17B10
SCHEMBL25276068 0.80 KMT2A (0.43) ACLYALDH1A1TSHRNOTUMTP53
SCHEMBL30733423 0.76 KCNN4 (0.47) ACLYALDH1A1NOTUMPKMKCNN4
SCHEMBL30733401 0.76 NOTUM (0.45) ACLYNOTUMNPY5R
SCHEMBL25282082 0.76 ACLY (0.40) ACLYALDH1A1NOTUMPKMATM
SCHEMBL25238614 0.75 NOTUM (0.42) ACLYALDH1A1NOTUMNPY5RKCNN4
SCHEMBL25281852 0.75 MEN1 (0.54) ACLYALDH1A1NOTUMATMNPY5R
SCHEMBL29386556 0.75 MEN1 (0.54) ACLYALDH1A1NOTUMATMNPY5R
SCHEMBL30733408 0.75 KMT2A (0.43) ACLYTSHRNOTUMHSD17B10NPY5R
SCHEMBL30733405 0.75 TSHR (0.50) ACLYALDH1A1TSHRNOTUMHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416262-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416262-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 ACLY 3265/4885BRD4 1470/4885ALDH1A1 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.